Stein 2000

Methods	ALLOCATION CONCEALMENT: unclear BLINDING: at least one measure was assessed by an independent assessor blind to treatment allocation
Participants	DIAGNOSIS: DSM‐IV panic disorder with or without agoraphobia (percent agoraphobic not given; however, the average score for FQ‐Ag was around 10.5 and 16.1, indicating most had at least some agoraphobia) AGE: mean=33.8 years SEX: 73% women HISTORY: None of the enrolled subjects reported taking benzodiazepines. PSYCHIATRIC COMORBIDITY: Major depressive disorder with melancholic features, schizophrenia, current substance abuse/dependence were excluded. MEDICAL COMORBIDITY: Seizure disorder, thyroid disease were excluded.
Interventions	ACUTE PHASE: 10 weeks 1. paroxetine (mean=32.4 mg/d) + CBT (2 sessions only, using self‐help book, relaxation tape, cognitive restructuring, breathing control, graded exposure) 2. placebo + CBT ACUTE PHASE CO‐INTERVENTION: None of the subjected entrolled reported taking benzo. MAINTENANCE: ‐ MODE OF DISCONTINUATION: ‐ FOLLOW‐UP: ‐
Outcomes	RESPONSE: "Much" or "very much improved" on CGI Improvement REMISSION: panic free GLOBAL: ‐ PANIC ATTACK: frequency of panic attacks AGORAPHOBIA: FQ‐Ag GENERAL ANXIETY: Beck Anxiety Inventory DEPRESSION: Beck Depression Inventory FUNCTIONING: Sheehan Disability Scale
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear